Biotechnology company Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative drug-delivery platform DehydraTECH(TM) alters the way cannabinoids enter the bloodstream, which results in increased absorption. A recent article discussing LXRP reads, “Its proprietary technology promises multiple advantages in cannabinoid edibles. First, it masks the undesirable taste typically found in cannabinoid edibles, eliminating the need to add sweetening agents and enabling sugar-free options. Second, it increases the product’s absorption rate, with absorption occurring at two- to five-times higher rates than other edibles. Finally, it reduces the time of onset; effects of the product are felt within 15–20 minutes of consumption rather than the typical 60–120 minutes. In a March 2016 focus study, subjects ranked Lexaria’s formulation as the best tasting and most palatable option. They also found it to deliver the highest-quality THC experience overall.”
To view the full article, visit http://ibn.fm/ZkEsd
About Lexaria Bioscience Corp.
Lexaria Bioscience has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the United States and Australia for utilization of its DehydraTECH delivery technology. Lexaria’s technology provides increases in intestinal absorption rates, more rapid delivery to the bloodstream, and important taste-masking benefits for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
